The in vitro activity 6f lomefloxacin , a new difluorinated quinolone, was compared with those ot ofloxacin, ciprbfloxacin, fleroxacin, amoxicillin, cefuroxime, and trimethoprim against 585 recent clinical isolates and other strains with known mechanisms of resistance. The MICs of lomefloxacin against 90% of the members of the family Enterobacteriaceae, Pseudomonas aeruginosa, and staphylococci were between 0.25 and 4 ,ug/ml. Ninety percent of Neisseria sp. and Haemophilus influenzae were susceptible to <0.06 ,ug/ml, and streptococci (including Streptococcus pyogenes, Streptococcus pneumoniae, and enterococci) and Bacteroidesfragiis were susceptible to 8 ,ug/inl. Lomefloxacin was comparable in activity to fleroxacin and ofloxacin, but it was less active than ciprofloxacin. There was cross-resistance between the quinolone group of antimicrobial agents. The protein binding of lomefloxacin was 15.4%, and serum had little effect on the activity of the compound. However, urine at pH 5.0 decreased the activity by two-to eightfold compared with that at pH 7.0.
Susceptibility testing. The susceptibilities of the strains to the compounds were studied by a routine agar plate dilution method. The inocula were prepared as follows. For all strains except streptococci (including Streptococcus pneumoniae), Neisseria spp., Haemophilus influenzae, and anaerobes, the organisms were grown overnight in nutrient broth to yield a viable count of about 109 CFU/ml. Streptococci, H. influenzae, and Neisseria spp. were grown in brain heart infusion broth (Oxoid Ltd., Basingstoke, England) plus 1% The medium used for the agar dilution procedure was Iso-Sensitest agar (pH 7.2; Oxoid) and was supplemented with 5% horse blood-1% supplement C, to support growth of streptococci, H. influenzae, and Neisseria spp.; for anaerobes Wilkins-Chalgren agar was used.
All plates were incubated in air at 37°C for 24 h, except for the following. The anaerobes were grown in an anaerobic cabinet in an atmosphere of 10% hydrogen-10% carbon dioxide-80% nitrogen; H. influenzae and Neisseria spp. were incubated in air enriched with 6% carbon dioxide. In addition, Staphylococcus aureus was also incubated in air at 30°C, with 5% sodium chloride added to the medium. The MIC of the antibiotic was defined as that concentration (in micrograms per milliliter of agar) at which no more than two colonies were detected. In the case of the higher inoculum a slight haze of growth was ignored. a Centriflo cone (Amicon Corp., Lexington, Mass.) with an exclusion limit of 50,000 daltons. The concentrations of lomefloxacin used were 2, 5, and 10 ,ug/ml. The ultrafiltrate (after pH adjustment with CO2 gas to precentrifugation values) was assayed by a microbiological method against standards prepared in phosphate buffer at pH 6.5 (the pH of the ultrafiltrate). The indicator organism was Escherichia coli Sch 12655 (from Schering Laboratories, Bloomfield, N.J.), and the medium was Oxoid antibiotic no. 1. The activities of lomefloxacin, ciprofloxacin, and tetracycline against three freshly isolated strains of Chlamydia trachomatis were determined by using a recently developed fluorescent antibody method (5a). Briefly, McCoy cell cover slip cultures treated with 5-iodo-2-deoxyuridine were infected with approximately 1,000 inclusion-forming units of Chlamydia trachomatis. The infected monolayers were then exposed to the various concentrations of the antimicrobial agents for 48 h and then stained by the immunofluorescent Imagen chlamydia test (Boots, Nottingham, England). The MIC was defined as the lowest concentration of antimicrobial agent which inhibited all inclusion development. The minimum lethal concentration was defined as the lowest concentration which inhibited inclusion development in cell sheets exposed to antimicrobial agents for 48 h and then reincubated in antibiotic-free medium for an additional 48 h.
RESULTS
The results obtained from 615 isolates tested at an inoculum of 104 CFU are summarized in Table 1 (included are data for the clinical isolates and P-lactamase producers, but not those for laboratory-derived mutants). Against members of the family Enterobacteriaceae, lomefloxacin displayed a degree of activity similar to those of fleroxacin and ofloxacin and was fourfold less active than ciprofloxacin. The Enterobacteriaceae tended to be susceptible to '1 ,ug of lomefloxacin per ml, with the following exceptions. Serratia sp. (MIC for 90% of the strains tested [MIC0], 4 p.g/ml) tended to be less susceptible to all the quinolones investigated. For Klebsiella pneumoniae (MICg, 2 pg/ml) the results were biased by the inclusion of three isolates with MICs of .4 ,ug/ml, which were isolated from clinical material and which were known to be resistant to other quinolones. Included in the study of the Enterobacteriaceae were strains known to be resistant to nalidixic acid. The nalidixic acid-resistant strains tended to be two-to fourfold less susceptible to lomefloxacin, like the other quinolones studied, compared with the nalidixic acid-susceptible strains of the same genus. Similarly, those strains included because they demonstrated resistance to the new quinolones showed cross-resistance to lomefloxacin ( Table 2 ). Also included in Table 2 are results for four laboratory-produced mutants of Escherichia coli KL-16, gyrA, nalB, naiC, and nalD. As expected, the gyrA, nalB, and nalD strains were fourfold less susceptible than the wild type; and the nalC strain showed a greater susceptibility. Strains with characterized ,-lactamases from Richmond and Sykes (5) groups I to V did not demonstrate any decrease in susceptibilities to the quinolones studied but did, as appropriate, show decreased susceptibilities to cefuroxime and amoxicillin.
The activity of lomefloxacin against Pseudomonas aeruginosa was comparable to those of fleroxacin and ofloxacin. Three strains were included which were isolated from treatment failures from a ciprofloxacin clinical trial; for these strains, lomefloxacin MICs were 8-to 16-fold greater; and these strains were less susceptible to the other quinolones (for example, ofloxacin MICs of 8, 8, and 16 ,ug/ml). Lomefloxacin showed a similar poor degree of activity as the other quinolones against Bacteroides fragilis. Clostridium perfringens (seven strains) was more susceptible to lomefloxacin (mode MIC, 2 jig/ml) than were the six strains of Clostridium difficile studied (mode MIC, 16 j,g/ml) ( Table   3 ). Peptostreptococci were similarly less susceptible to all the quinolones than to cefuroxime. Eight strains of Peptococcus spp. again showed moderate susceptibilities to lomefloxacin (mode MIC, 4 ,ug/ml) and the other quinolones studied (data not shown).
Ofloxacin was the most active quinolone tested against strains of Staphylococcus aureus, but lomefloxacin was approximately as active as ciprofloxacin. Its activity was similar at 30°C to that at 35°C. Generally, all the quinolone agents were up to fourfold less active against Staphylococcus epidermidis than they were against Staphylococcus aureus. Ciprofloxacin was the most active quinolone studied against Staphylococcus saprophyticus, with these strains being fourfold more susceptible to ciprofloxacin than to lomefloxacin. Enterococci (Lancefield group D), Streptococcus pneumoniae, and Streptococcus pyogenes (Lancefield group A) were all markedly less susceptible to all the quinolones studied compared with their susceptibilities to amoxicillin. Lomefloxacin and fleroxacin were the least active agents against these strains and 10 Lancefield group B streptococci (data not shown).
The MICs of lomefloxacin for the three strains of Chlamydia trachomatis were 2 ,uag/ml; the MICs of ciprofloxacin were 1, 1, and 2 ,ugIml; the MICs of tetracycline were 0.12 jig/ml. The minimum lethal concentrations were identical to the MICs for lomefloxacin; 1, 2, and 2 jig/ml for ciprofloxacin; and 0.25 ,ug/ml for tetracycline.
An increase in inoculum from 104 to 106 CFU had very little effect on the activity of any of the quinolones studied (data not shown). A more marked effect was seen with trimethoprim, and those strains which produced appropriate P-lactamases showed a marked effect (that is, a >fourfold increase in MIC) against the P-lactams studied. whereas we found the strains to have an MIC90 of 4 ,ug/ml.
Although Bacteroides fragilis is relatively resistant to lomefloxacin, the strains we studied were two-to fourfold more susceptible than those described by Hirose et al. (2) (MIC%0, 25 ,ug/ml). We cannot offer any explanation for these differences but note that the results we obtained in this study with the agents being compared were similar to those published previously (1, 6 ). Lomefloxacin appears to be similar to other agents of this class, in that cross resistance with the other quinolones was observed. In particular, those clinical isolates and laboratory mutants previously known to exhibit resistance to earlier quinolones were less susceptible to lomefloxacin. However, strains known to be resistant to other groups of antimicrobial agents, such as the P-lactams, demonstrated no cross resistance to lomefloxacin or the other quinolones.
The activity of lomefloxacin against Chlamydia trachomatis was encouraging, in that it was comparable to the activity of ciprofloxacin and there was no difference between the inhibitory and lethal concentrations. A clinical study of lomefloxacin in chlamydial urethritis is therefore suggested.
As might be expected with a compound with low protein binding, serum had little effect on activity. In common with other quinolones (7), pH had a more marked effect on the MIC but, surprisingly, not on the MBC; bactericidal activity was similar to, or at most fourfold less, in urine at pH 5 compared with that at pH 7. Preliminary studies on the pharmacokinetics of lomefloxacin suggest that maximum levels in serum of about 2 ,ug/ml are achieved rapidly after a 200-mg oral dose, about twice those after a similar dose of norfloxacin (S. Kamidono, A. Fujii, H. Nagata, J. Ishigani, 15th International Congress of Chemotherapy, abstr. no. 1340, 1987) . This suggests that systemic infections caused by the common Enterobacteriaceae, H. influenzae, Neisseria spp. and staphylococci should be amenable to therapy. In the case of infections caused by less susceptible strains such as Pseudomonas aeruginosa, Streptococcus pneumoniae, and other streptococcal species, it is possible that a larger dose is required or that for treatment to be effective the infection should occur at a site at which the agent is concentrated. In addition, another favorable property of lomefloxacin is its relatively long serum elimination half-life of 7 to 8 h (M. Nakashima, T. Uematsu, Y. Takiguchi, A. Mizuno, M. Kanamaru, A. Tsuji, S. Kubo, 0. Nagata, E. Okezaki, and Y. Takahara, 26th Intersci. Conf. Antimicrob. Agents Chemother. abstr. no. 430, 1986) , suggesting a possible once daily dosing.
